

IPSOGEN licenses the Genomic Grade™ to improve Breast Cancer diagnosis & treatment decision

Marseille, France, January 28, 2007 – IPSOGEN SAS, a leading molecular diagnostic company based in France and Connecticut, USA announced today the signature of a license agreement with Université Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.

The Genomic Grade™ is a genomic index invented by Pr. Christos Sotiriou & Pr. Martine Piccart, from the Bordet Institute, Brussels and Dr. Mauro Delorenzi from the Swiss Institute for Cancer Research (ISREC), Lausanne, two leading European cancer research institutes.

In their seminal paper published in 2006 in the Journal of the National Cancer Institute⁽¹⁾, Pr. Sotiriou & colleagues showed that the grade, as measured today and since 1890 by histological examination of tumor sections under a microscope, could not describe the proliferation ability of 30 to 60 % of tumors. By contrast, the Genomic Grade™ could capture proliferation in most tumors and showed superior prognostic & classification value over conventional grading methods. These findings have been validated in more than 1'100 patients, including a second study published last year in the Journal of Clinical Oncology⁽²⁾.

The Genomic Grade™ represents the common core feature of the main breast cancer prognostic genomic signatures published worldwide, as shown by a meta-analysis presented by Pr. Piccart at the St. Gallen Breast Cancer conference in March 2007. Importantly, the Genomic Grade™ can be measured by both DNA microarray and multiplex PCR technologies, as presented at the 2007 meeting of the American Society of Clinical Oncology.

“The genomic field was quite a chaos where each actor tries to sell its own prognostic factor in breast cancer. But all these prognostic factors overlap and the common factor is the grade, as pathologists know. We are very grateful to the ULB team for making this point clear, and for giving IPSOGEN the opportunity to offer to pathologists a precise & consensual way to grade tumors, with the Genomic Grade™. IPSOGEN will integrate the Genomic Grade™ as the cornerstone of its offer of breast cancer profiling tests that will be launched in 2008. ” says, Vincent Fert, President and CEO of IPSOGEN.

“IPSOGEN's vision is to translate the genomic profile of each tumor into reliable, intelligible and decisive information for pathologists, oncologists and patients. The Genomic Grade™ perfectly exemplifies this vision: it is reliable, meaningful, and

immediately useful to improve treatment decisions in about 50 % of breast cancer patients. This licensing agreement shows that world-leading researchers & institutions consider IPSOGEN as the best partner for realizing this vision” added Dr. Jean-Marc Le Doussal, Director of Breast Cancer program at IPSOGEN.

About IPSOGEN

IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide and personalize treatment options in cancers. IPSOGEN has built a comprehensive portfolio of unique products in blood cancers available in over 50 countries all over the world to leading institutions involved in cancer care. IPSOGEN products are registered as IVD in Europe. IPSOGEN recently established commercial and service agreements with major testing laboratories in the United States, Canada and Europe, including Laboratory Corporation of America holding (LabCorp®), Warnex Inc. and DNA Vision.

IPSOGEN is headquartered in Marseille, France and has its U.S. offices in New Haven, Connecticut. For more information on IPSOGEN, please visit: <http://www.ipsogen.com>.

About ULB (Université Libre de Bruxelles, Belgium)

The Université Libre de Bruxelles (ULB, <http://www.ulb.ac.be/>) is a multicultural institution and a comprehensive university providing academic tuition in all disciplines and study cycles. With its three Nobel Prize winners, a Fields medal, a Wolf Prize for physics, two Marie Curie Prizes and 29% of the Francqui prizes awarded, the ULB is also a major research centre which is recognized by the academic community the world over.

The ULB also has a specialist institute for studying cancer – the Institut Bordet (<http://www.bordet.be/>). A fundamental aspect of the Institut Bordet is the close integration of research and practical oncology. A number of clinical research programs are carried out in cooperation with national and international centers, especially in the framework of the EORTC (European Organization for Research and Treatment of Cancer) that was founded at the Institute Jules Bordet in 1964.

Contacts

IPSOGEN: – Tel: +33 4 9129 3090 - Fax: + 33 4 9129 3099

Vincent FERT, CEO – fert@ipsogen.com

Jean-Marc Le Doussal, Director of Breast Cancer Program – ledoussal@ipsogen.com

References

(1) Sotiriou et al. *Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis*. [J Natl Cancer Inst](#). 2006 Feb 15;98(4):262-72

(2) Loi et al. *Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade*. [J Clin Oncol](#). 2007 Apr 1;25(10):1239-46.